Resources for Your Practice
View
MG-ADL Questionnaire
Online Myasthenia Gravis
Activities of Daily Living
Assessment Questionnaire
For reimbursement payers may require MG-ADL and/or QMG to be completed
View
MG Mechanism of Disease Video (<3 min)
See the role of complement proteins in the degradation of the NMJ
Resources for Your Patients
View and Download
OneSource Personalized Patient Support from Alexion
Support Program Patient Brochure
View and Download
SOLIRIS®: Patient Safety Card
View
MG-ADL Questionnaire
Online Myasthenia Gravis
Activities of Daily Living
Assessment Questionnaire
For reimbursement payers may require MG-ADL and/or QMG to be completed
SOLIRIS® (eculizumab) is indicated in adult patients with generalized Myasthenia Gravis (gMG).
SOLIRIS® was studied in clinical trials in patients who were anti-acetylcholine receptor (AChR) antibody positive and refractory, defined as failure of treatment with two or more immunosuppressive therapies (ISTs) either in combination or as monotherapy, or failed at least one IST and required chronic plasmapheresis, plasma exchange (PE), or intravenous immunoglobulin (IVIg) to control symptoms. Patients continued to receive standard therapy throughout the pivotal clinical trial.
SOLIRIS® should be administered by a qualified healthcare professional.
WARNING: SERIOUS MENINGOCOCCAL INFECTIONS
Cases of serious or fatal meningococcal infections have been reported in patients treated with SOLIRIS®. Meningococcal infections may become rapidly life-threatening or fatal if not recognized and treated early.
- Comply with the most current National Advisory Committee on Immunization (NACI) recommendations for meningococcal vaccination in patients with complement deficiencies.
- All patients must be vaccinated with meningococcal vaccines prior to, or at the time of, initiating SOLIRIS®, unless the risks of delaying SOLIRIS® therapy outweigh the risks of developing a meningococcal infection; revaccinate according to current medical guidelines for vaccine use.
- All patients must be monitored for early signs of meningococcal infections, evaluated immediately if infection is suspected, and treated with antibiotics, if necessary.
Vaccination may not prevent all meningococcal infections.
Contraindications
Do not initiate SOLIRIS® therapy in patients:
- With unresolved Neisseria meningitidis infection.
- Who are not currently vaccinated against Neisseria meningitidis (unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination).